The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•27 February 2026•

1 min read

Ionis Pharmaceuticals Raises Tryngolza Revenue Outlook, Targets 2028 Breakeven

Key Facts

1Ionis raised Tryngolza's peak revenue estimate to over $2 billion following strong clinical data.

2The company projects total peak annual product revenue exceeding $4 billion, plus $2 billion in royalties.

Ionis Pharmaceuticals (IONS) has significantly upgraded its long-term financial guidance following strong clinical performance across its drug pipeline. The company raised its peak annual revenue estimate for Tryngolza to over $2 billion, driven by positive data in treating severe hypertriglyceridemia. Management now projects total peak annual product revenue to exceed $4 billion, supplemented by an additional $2 billion in royalty streams. Furthermore, Ionis has established a clear strategic roadmap to reach cash-flow breakeven by 2028. These updates highlight the company's robust fundamental outlook and its successful transition toward commercial-stage growth in the biotechnology sector.